ArticleRevista da Escola de Enfermagem da U S P2025
Effects of tocilizumab on renal function and oxidative stress in an experimental model of acute ischemic kidney injury.
Article in Revista da Escola de Enfermagem da U S P, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute kidney injury (AKI) results from renal damage that triggers oxidative stress, inducing apoptosis, structural abnormalities in cells and their organelles, and even mitochondrial DNA instability. Tocilizumab is a monoclonal antibody inhibitor of interleukin-6, initially used to treat rheumatoid arthritis and later tested for COVID-19 treatment, which may have a protective effect on AKI.
objectiveTo evaluate the effect of tocilizumab on renal function and oxidative profile in rats with ischemic AKI.
methodsThis is an experimental study using a quantitative approach with animals. The animals were randomized into four groups: SHAM (control); TCZ (tocilizumab); I/R (ischemia/renal reperfusion, clamping of both renal pedicles for 30 minutes); and TCZ + I/R. Tests were performed to assess renal function (inulin clearance and plasma creatinine), renal oxidation (urinary peroxides, malondialdehyde-derived oxidative substances), and endogenous antioxidant agents (thiols).
resultsRegarding renal function, the treated group showed improvement in inulin clearance (IR 0.24 ± 0.3 vs TCZ + IR 0.65 ± 0.05; p < 0.05) and plasma creatinine levels (IR 2.3 ± 0.6 vs TCZ + IR 0.8 ± 0.3; p < 0.05). Analysis of the oxidative profile revealed a reduction in peroxides, confirming an attenuation of the redox mechanism (IR 15.8 ± 2.8 vs. TCZ + IR 3.7 ± 1.3; p < 0.05).
conclusionTocilizumab demonstrated renoprotective effects, improving renal function and reducing oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.